Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 1317 matching drugs for FLT1 — including drugs targeting any of its 16 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
sunitinib FLT1 Direct yes 5
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FLT1 Direct 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FLT1 Direct 4
pembrolizumab, belzutifan, lenvatinib FLT1 Direct 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FLT1 Direct 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 FLT1 Direct 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a FLT1 Direct 2
lenvatinib, pembrolizumab FLT1 Direct 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate FLT1 Direct 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a FLT1 Direct 2
nintedanib FLT1 Direct yes 2
nintedanib, pembrolizumab FLT1 Direct 2
pazopanib FLT1 Direct yes 2
pembrolizumab, lenvatinib FLT1 Direct 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu FLT1 Direct 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin FLT1 Direct 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery FLT1 Direct 2
regorafenib FLT1 Direct yes 2
regorafenib, laboratory biomarker analysis FLT1 Direct 2
sorafenib, administered orally, ct/mri FLT1 Direct 2
atezolizumab, tivozanib FLT1 Direct 1
axitinib FLT1 Direct yes 1
axitinib, avelumab FLT1 Direct 1
axitinib, axitinib plus lomustine FLT1 Direct 1
biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib FLT1 Direct 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab FLT1 Direct 1
cisplatin, pemetrexed disodium, sorafenib FLT1 Direct 1
everolimus, sorafenib FLT1 Direct 1
everolimus, vatalanib, pharmacological study, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, ultrasound imaging FLT1 Direct 1
fruquintinib, sintilimab FLT1 Direct 1
fruquintinib, tislelizumab, radiotherapy FLT1 Direct 1
gemcitabine, erlotinib, sorafenib FLT1 Direct 1
gemcitabine, placebo, sorafenib FLT1 Direct 1
gemcitabine, sorafenib, radiotherapy FLT1 Direct 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff FLT1 Direct 1
gemcitabine, sunitinib FLT1 Direct 1
h101, tislelizumab, lenvatinib FLT1 Direct 1
hydroxyurea, imatinib mesylate, vatalanib FLT1 Direct 1
imt-009, fruquintinib FLT1 Direct 1
lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil FLT1 Direct 1
lenvatinib, bevacizumab FLT1 Direct 1
oxaliplatin, sorafenib FLT1 Direct 1
paclitaxel, irinotecan, pembrolizumab, mk-4830, lenvatinib, sacituzumab tirumotecan, antihistamine, h2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) FLT1 Direct 1
pazopanib, 5-fu, oxaliplatin, leukovorin (flo) FLT1 Direct 1
pazopanib, lapatinib FLT1 Direct 1
pazopanib, placebo FLT1 Direct 1
pegilodecakin, paclitaxel or docetaxel and carboplatin or cisplatin, folfox (oxaliplatin/leucovorin/5-fluorouracil), gemcitabine/nab-paclitaxel, capecitabine, pazopanib, pembrolizumab, paclitaxel, nivolumab, gemcitabine/carboplatin FLT1 Direct 1
pembrolizumab, coformulation favezelimab/pembrolizumab, mk-4830, lenvatinib, irinotecan, paclitaxel FLT1 Direct 1
pembrolizumab, lenvatinib, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, paclitaxel FLT1 Direct 1
radiation therapy, temozolomide, sorafenib FLT1 Direct 1
regorafenib, lomustine FLT1 Direct 1
regorafenib, nivolumab, capeox, folfox regimen FLT1 Direct 1
regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil FLT1 Direct 1
regorafenib, temozolomide FLT1 Direct 1
ryz101, everolimus, sunitinib, octreotide, lanreotide FLT1 Direct 1
selpercatinib FLT1 Direct yes 1
serplulimab, lenvatinib, paclitaxel/paclitaxel-albumin/paclitaxel liposome FLT1 Direct 1
sorafenib FLT1 Direct yes 1
sorafenib, erlotinb FLT1 Direct 1
sorafenib, rad001 FLT1 Direct 1
sorafenib, radiofrequency ablation (rfa) or surgery, everolimus, lanreotide FLT1 Direct 1
sunitinib, placebo FLT1 Direct 1
sunitinib, radiation FLT1 Direct 1
sunitinib, sunitinib FLT1 Direct 1
tace, lenvatinib, combined with tislelizumab group FLT1 Direct 1
tace, tislelizumab, lenvatinib FLT1 Direct 1
temozolomide, lomustine, regorafenib, radiation, paxalisib, val-083, vt1021, troriluzole, adi-peg 20 FLT1 Direct 1
temozolomide, vatalanib, adjuvant therapy, radiation therapy FLT1 Direct 1
tivozanib FLT1 Direct 1
topotecan, pazopanib FLT1 Direct 1
topotecan, sorafenib FLT1 Direct 1
trc 105, sorafenib FLT1 Direct 1
vatalanib FLT1 Direct 1
vemurafenib, sorafenib FLT1 Direct 1
av9 FLT1 Direct yes 0
cabozantinib FLT1 Direct yes 0
cabozantinib s-malate FLT1 Direct yes 0
lenvatinib FLT1 Direct yes 0
lenvatinib mesylate FLT1 Direct yes 0
nintedanib esylate FLT1 Direct yes 0
pazopanib hydrochloride FLT1 Direct yes 0
sorafenib tosylate FLT1 Direct yes 0
sunitinib malate FLT1 Direct yes 0
tivozanib hydrochloride FLT1 Direct yes 0
vandetanib FLT1 Direct yes 0
sunitinib PDGFRA SSL via PDGFRA yes 5
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FGFR1 SSL via FGFR1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PDGFRA SSL via PDGFRA 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab VEGFA SSL via VEGFA 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FGFR1 SSL via FGFR1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) PDGFRA SSL via PDGFRA 4
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine CMPK1 SSL via CMPK1 3
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine RRM1 SSL via RRM1 3
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine TYMS SSL via TYMS 3
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine VEGFA SSL via VEGFA 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FGFR1 SSL via FGFR1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FYN SSL via FYN 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PDGFRA SSL via PDGFRA 3
bevacizumab VEGFA SSL via VEGFA 3
capecitabine, cisplatin TYMS SSL via TYMS 3
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.